Data / Research funding / California / Beckman Research Institute/city of Hope
Beckman Research Institute/city of Hope: 264 NIH awards ($395.9M) and 1 NSF award ($50K), fiscal years 2021 to 2026
Beckman Research Institute/city of Hope in Duarte, CA is funded under 264 NIH awards ($395.9M) and 1 NSF award ($50K) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- NPH1VN32EWN5
- State
- California
Awards
265 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $21,571,641 | August 1, 1997 | November 30, 2027 | CARPTEN, JOHN D. | reporter.nih.gov |
| Integrated Islet Distribution Program (U24) - 2021 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $14,918,013 | September 30, 2012 | July 31, 2027 | NILAND, JOYCE CAROL | reporter.nih.gov |
| Renewal of the Human Islet Research Enhancement Center (HIREC) for the Type-1-Diabetes-Focused Human Islet Research Network (HIRN). | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $7,703,361 | September 15, 2014 | June 30, 2029 | KADDIS, JOHN S. | reporter.nih.gov |
| Innovative Infrastructure to Enhance and Sustain the California Teachers Study Cohort | NIH | National Cancer Institute | 2021 to 2024 | $5,912,553 | September 1, 2015 | August 31, 2025 | LACEY, JAMES V | reporter.nih.gov |
| A Human iPSC-based Cell Therapy for Canavan Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $5,276,950 | June 15, 2021 | May 31, 2027 | SHI, YANHONG | reporter.nih.gov |
| CureSC Manufacturing Resource Platform | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $5,179,238 | September 27, 2019 | September 30, 2026 | CARDOSO, ANGELO A. | reporter.nih.gov |
| Precision approaches to refining TP53-associated cancer risk | NIH | National Cancer Institute | 2021 to 2023 | $5,115,949 | September 18, 2019 | August 31, 2025 | GRUBER, STEPHEN B | reporter.nih.gov |
| Mucus-degrading intestinal bacteria and toxicities of hematopoietic cell transplantation | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $5,032,505 | September 21, 2024 | July 31, 2029 | JENQ, ROBERT | reporter.nih.gov |
| Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN | NIH | National Cancer Institute | 2023 to 2025 | $4,791,191 | March 28, 2014 | February 28, 2027 | DANILOV, ALEXEY V. | reporter.nih.gov |
| Unmasking the roles of viral glycoproteins in oral transmission of KSHV | NIH | National Cancer Institute | 2021 to 2025 | $4,786,354 | September 1, 2021 | August 31, 2026 | OGEMBO, JAVIER GORDON | reporter.nih.gov |
| Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability | NIH | National Cancer Institute | 2021 to 2025 | $4,645,634 | September 13, 2021 | August 31, 2027 | PORTNOW, JANA | reporter.nih.gov |
| City of Hope Lymphoma SPORE | NIH | National Cancer Institute | 2021 to 2022 | $4,632,203 | September 2, 2004 | August 31, 2025 | FORMAN, STEPHEN J | reporter.nih.gov |
| KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,284,115 | March 22, 2021 | February 28, 2027 | OGEMBO, JAVIER GORDON | reporter.nih.gov |
| Exosome-based microRNA biomarkers for Non-invasive and Early Detection of Pancreatic Cancer | NIH | National Cancer Institute | 2021 to 2025 | $4,072,882 | September 1, 2017 | July 31, 2028 | GOEL, AJAY | reporter.nih.gov |
| 1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership | NIH | National Cancer Institute | 2023 to 2025 | $4,072,339 | September 22, 2023 | August 31, 2028 | SEEWALDT, VICTORIA L. | reporter.nih.gov |
| Human natural killer cells: Advancing biology and clinical applications | NIH | National Cancer Institute | 2021 to 2025 | $3,769,374 | July 21, 2017 | June 30, 2032 | CALIGIURI, MICHAEL A | reporter.nih.gov |
| Validation of epigenomic biomarkers for thyroid cancer diagnostics | NIH | National Cancer Institute | 2021 to 2025 | $3,647,565 | June 15, 2021 | November 30, 2026 | HAHN, MARIA | reporter.nih.gov |
| Mechanism of estrogen independent proliferation in ER+ breast cancer cells | NIH | National Cancer Institute | 2021 to 2025 | $3,641,042 | September 1, 2021 | August 31, 2027 | BILD, ANDREA HOPE | reporter.nih.gov |
| Geriatric Oncology Research Infrastructure to Improve Clinical Care | NIH | National Institute on Aging | 2021 to 2025 | $3,602,031 | April 1, 2018 | June 30, 2028 | DALE, WILLIAM | reporter.nih.gov |
| Leveraging Digital Health Solutions to Reduce Learning and Functional Disparities in Children with Cancer - Administrative Supplement | NIH | National Cancer Institute | 2022 to 2025 | $3,407,172 | July 5, 2022 | June 30, 2027 | PATEL, SUNITA K | reporter.nih.gov |
| Self-Management to Optimize Survivorship Care and Outcomes in Lung and Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2024 | $3,217,584 | April 2, 2020 | March 31, 2026 | SUN, VIRGINIA CHIH-YI | reporter.nih.gov |
| Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers | NIH | National Cancer Institute | 2021 to 2024 | $3,192,137 | April 1, 2020 | March 31, 2026 | ARMENIAN, SARO | reporter.nih.gov |
| Extreme weather, air pollution, and stroke among an aging female population | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $3,191,631 | September 2, 2021 | June 30, 2027 | WANG, SOPHIA S | reporter.nih.gov |
| City of Hope Clinical Oncology Career Research Development Program | NIH | National Cancer Institute | 2021 to 2024 | $3,057,842 | September 9, 1992 | July 31, 2025 | MORTIMER, JOANNE E. | reporter.nih.gov |
| Extracellular Vesicle-mediated islet immune cross talk in Type 1 Diabetes pathogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,020,296 | September 15, 2022 | April 30, 2027 | REIJONEN, HELENA KRISTIINA | reporter.nih.gov |
| Cbfb in RORgt-regulated T cell function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,010,210 | May 1, 2014 | May 31, 2029 | SUN, ZUOMING | reporter.nih.gov |
| Targeting MicroRNAs to Eradicate Leukemia Stem Cells | NIH | National Cancer Institute | 2021 to 2025 | $2,990,517 | August 1, 2017 | July 31, 2027 | KUO, YA-HUEI | reporter.nih.gov |
| Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $2,929,456 | August 1, 2020 | April 30, 2026 | BROWN, CHRISTINE | reporter.nih.gov |
| Information flow and state transitions at the system and multi-dimensional scales in leukemia progression | NIH | National Cancer Institute | 2021 to 2024 | $2,901,922 | May 1, 2020 | April 30, 2025 | ROCKNE, RUSSELL CHRISTIAN | reporter.nih.gov |
| The role of the intestinal microbiome in cancer immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $2,811,009 | August 1, 2023 | July 31, 2030 | VAN DEN BRINK, MARCEL R M | reporter.nih.gov |
| Transcriptional Regulation by Angiotensin II in Vascular Smooth Muscle Cells | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,801,471 | January 1, 2011 | April 30, 2026 | NATARAJAN, RAMA | reporter.nih.gov |
| Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,785,889 | February 1, 2020 | January 31, 2026 | ARMENIAN, SARO | reporter.nih.gov |
| A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,785,861 | September 1, 2022 | June 30, 2027 | RODRIGUEZ-RODRIGUEZ, LORNA | reporter.nih.gov |
| Integration of epidemiology, pathology, immunology and outcomes in colorectal cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,735,518 | September 22, 2022 | August 31, 2027 | GRUBER, STEPHEN B | reporter.nih.gov |
| Engineered anti-PSCA antibodies for immunoPET and targeted therapy of pancreatic cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,731,178 | January 1, 2022 | December 31, 2026 | WU, ANNA M | reporter.nih.gov |
| DNA repair gene mutations and prostate cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,728,204 | December 2, 2019 | November 30, 2025 | SHEN, BINGHUI | reporter.nih.gov |
| Conformal Total Body and Marrow Irradiation for Leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,727,228 | September 13, 2011 | December 31, 2025 | HUI, SUSANTA K | reporter.nih.gov |
| Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans | NIH | National Cancer Institute | 2021 to 2025 | $2,706,923 | May 1, 2021 | April 30, 2027 | ROSEN, STEVEN TERRY | reporter.nih.gov |
| BAFF-R CAR T cell therapy for ALL | NIH | National Cancer Institute | 2022 to 2025 | $2,663,058 | April 18, 2022 | March 31, 2027 | WANG, XIULI | reporter.nih.gov |
| Role of the unfolded protein response in pathological cardiac remodeling | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,591,867 | June 1, 2017 | June 30, 2027 | WANG, ZHAO | reporter.nih.gov |
| Pathogenesis, prevention and treatment of corticosteroid-resistant gut GVHD | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,553,048 | February 15, 2023 | January 31, 2027 | ZENG, DEFU | reporter.nih.gov |
| Environmental Chemical Body Burden and Prospective Breast Cancer Risk in the Cancer Prevention Study-3 Cohort | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,549,349 | July 20, 2022 | April 30, 2027 | NEUHAUSEN, SUSAN L. | reporter.nih.gov |
| Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,499,820 | September 9, 2022 | August 31, 2028 | WANG, XIULI | reporter.nih.gov |
| Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,401,768 | July 9, 2021 | June 30, 2026 | CALIGIURI, MICHAEL A | reporter.nih.gov |
| The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,254,307 | March 1, 2022 | February 28, 2027 | CHEN, JIANJUN | reporter.nih.gov |
| Overcoming ibrutinib resistance in mantle cell lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $2,239,026 | February 1, 2021 | January 31, 2026 | DANILOV, ALEXEY V. | reporter.nih.gov |
| Targeting FTO to treat acute myeloid leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,229,526 | December 1, 2019 | November 30, 2025 | CHEN, JIANJUN | reporter.nih.gov |
| Air Pollution and Neighborhood Stressors as Determinants of Non-Small Cell Lung Cancer (NSCLC) Mutation Patterns and Recurrence | NIH | National Cancer Institute | 2024 to 2025 | $2,217,862 | May 10, 2024 | April 30, 2029 | ERHUNMWUNSEE, LORETTA | reporter.nih.gov |
| Combating Subclonal Evolution of Resistant Cancer Phenotypes | NIH | National Cancer Institute | 2021 | $2,195,349 | May 15, 2017 | June 30, 2023 | BILD, ANDREA HOPE | reporter.nih.gov |
| Develop age-relevant glial cellular models using human directly reprogrammed cells | NIH | National Institute on Aging | 2021 to 2025 | $2,191,200 | September 30, 2021 | May 31, 2027 | SHI, YANHONG | reporter.nih.gov |
| Exosomal biomarkers for the early detection of hepatocellular carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $2,166,339 | August 8, 2023 | July 31, 2028 | GOEL, AJAY | reporter.nih.gov |
| The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML | NIH | National Cancer Institute | 2022 to 2025 | $2,133,556 | January 1, 2022 | December 31, 2026 | MARCUCCI, GUIDO | reporter.nih.gov |
| Identifying and engaging a universal adjuvant for breaking macrophage immune tolerance in cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,127,301 | July 8, 2021 | March 31, 2027 | FENG, MINGYE | reporter.nih.gov |
| Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia | NIH | National Cancer Institute | 2023 to 2025 | $2,114,878 | July 19, 2023 | June 30, 2028 | KORTYLEWSKI, MARCIN | reporter.nih.gov |
| Elucidating the role of DNAPKcs in chromosomal break end joining and clastogen resistance | NIH | National Cancer Institute | 2021 to 2025 | $2,105,577 | July 1, 2021 | June 30, 2027 | STARK, JEREMY MICHAEL | reporter.nih.gov |
| Biomarkers, mechanisms and modulation of oxidative stress associated risk factors in carcinogenesis | NIH | Office of the Director, National Institutes of Health | 2022 to 2025 | $2,065,432 | September 14, 2022 | December 31, 2025 | LI, YUN ROSE | reporter.nih.gov |
| Targeting tumor-associated macrophages for triple-negative breast cancer treatment | NIH | National Cancer Institute | 2022 to 2025 | $2,060,620 | December 1, 2021 | November 30, 2026 | FENG, MINGYE | reporter.nih.gov |
| Targeting p38 gamma signaling to advance Cutaneous T Cell Lymphoma Therapy | NIH | National Cancer Institute | 2021 to 2023 | $2,047,877 | December 1, 2018 | November 30, 2024 | ROSEN, STEVEN TERRY | reporter.nih.gov |
| Scalable tools to effectively translate genomic discoveries into the clinic : Administrative Supplement | NIH | National Human Genome Research Institute | 2021 to 2024 | $2,031,092 | September 1, 2019 | June 30, 2025 | GRAY, STACY W. | reporter.nih.gov |
| TET2-mediated epitranscriptomic regulation in leukemia microenvironment | NIH | National Cancer Institute | 2023 to 2025 | $2,018,981 | September 21, 2023 | August 31, 2028 | CHEN, JIANJUN | reporter.nih.gov |
| Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target? | NIH | National Cancer Institute | 2021 to 2024 | $1,996,349 | April 1, 2020 | March 31, 2026 | MARCUCCI, GUIDO | reporter.nih.gov |
| Targeted radiation and immunocytokine therapy for CEA positive malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,994,976 | September 21, 2023 | August 31, 2028 | SHIVELY, JOHN ERNEST | reporter.nih.gov |
| The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $1,989,049 | July 1, 2021 | June 30, 2026 | NGO, VU NGUYEN | reporter.nih.gov |
| (PQ11) Immune modulatory effects of white button mushroom in prostate cancer - A translational research | NIH | National Cancer Institute | 2021 to 2023 | $1,970,965 | September 1, 2019 | August 31, 2025 | CHEN, SHIUAN | reporter.nih.gov |
| Retinoic Acid Induced Lymphangiogenesis for Post-surgical Lymphedema | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,961,343 | September 1, 2021 | November 30, 2023 | WONG, ALEX K. | reporter.nih.gov |
| Advancing Photoacoustic Tomography in breast imaging to predict response in breast cancers treated with neoadjuvant therapy | NIH | National Cancer Institute | 2023 to 2025 | $1,960,318 | July 3, 2023 | June 30, 2028 | LAI, LILY LAU | reporter.nih.gov |
| Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivation | NIH | National Cancer Institute | 2023 to 2025 | $1,953,422 | May 2, 2023 | April 30, 2028 | DIAMOND, DON J | reporter.nih.gov |
| Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma | NIH | National Cancer Institute | 2021 to 2024 | $1,945,311 | January 1, 2019 | December 31, 2025 | BROWN, CHRISTINE | reporter.nih.gov |
| Define the effect of CLU SNP on the risk to Alzheimer's disease | NIH | National Institute on Aging | 2022 | $1,942,962 | August 1, 2022 | July 31, 2025 | SHI, YANHONG | reporter.nih.gov |
| Functional Analysis of Structure Specific Nucleases in Genome Stability and Cancers | NIH | National Cancer Institute | 2021 to 2025 | $1,887,170 | September 20, 2016 | August 31, 2026 | ZHENG, LI | reporter.nih.gov |
| Circulating Extracellular Vesicles in the Pathogenesis of Type 1 Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,847,008 | August 24, 2021 | May 31, 2026 | VASAVADA, RUPANGI C | reporter.nih.gov |
| Microbial- based targeting of major extracellular matrix components for improved therapy of pancreatic cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,800,436 | September 9, 2022 | August 31, 2027 | MANUEL, EDWIN | reporter.nih.gov |
| Identification of small molecule inhibitors to exonuclease 1 for breast cancer treatment | NIH | National Cancer Institute | 2023 to 2025 | $1,797,046 | August 2, 2023 | July 31, 2027 | SHEN, BINGHUI | reporter.nih.gov |
| Targeting an atypical signaling hub to restore and protect whole body glucose homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,786,349 | September 12, 2014 | November 30, 2025 | THURMOND, DEBBIE C | reporter.nih.gov |
| Optimizing GVHD Prevention with Systems Pharmacology Models | NIH | National Cancer Institute | 2021 to 2023 | $1,776,007 | June 1, 2019 | May 31, 2025 | HORNE, DAVID A. | reporter.nih.gov |
| The role of miR-142 in regulatory T cell Development and function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,760,000 | September 17, 2020 | August 31, 2025 | BOLDIN, MARK P | reporter.nih.gov |
| Role of de novo pyrimidine biosynthesis in pathological cardiac remodeling | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,760,000 | March 1, 2022 | February 28, 2027 | WANG, ZHAO | reporter.nih.gov |
| Role of autoreactivity in pathogenesis of chronic graft versus host disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,758,526 | April 1, 2024 | February 29, 2028 | ZENG, DEFU | reporter.nih.gov |
| Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells | NIH | National Cancer Institute | 2021 to 2024 | $1,742,633 | December 1, 2019 | April 24, 2024 | YU, JIANHUA | reporter.nih.gov |
| The Role of Adipocyte Uridine Biosynthesis in Obesity and Diabetes Progression | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,742,400 | August 1, 2021 | July 31, 2026 | DENG, YINGFENG | reporter.nih.gov |
| Experimental-Computational Synthesis of Altered Immune Signaling in Breast Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,717,466 | September 16, 2019 | August 31, 2024 | LEE, PETER POON-HANG | reporter.nih.gov |
| Role of Protein Arginine Methyltransferase 9 in Acute Myeloid Leukemia Maintenance | NIH | National Cancer Institute | 2021 to 2024 | $1,695,047 | March 1, 2020 | February 28, 2025 | LI, LING | reporter.nih.gov |
| Integrative role of Rps6kb1 in pathological cardiac remodeling | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,693,072 | July 1, 2024 | April 30, 2028 | WANG, ZHAO | reporter.nih.gov |
| Combinational Targeting the Feed-forward Epigenetic Circuitry in Mixed Lineage Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $1,684,284 | December 1, 2023 | February 16, 2025 | CHEN, CHUN-WEI DAVID | reporter.nih.gov |
| Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy | NIH | National Cancer Institute | 2021 to 2023 | $1,679,695 | March 15, 2019 | February 28, 2025 | QUERFELD, CHRISTIANE | reporter.nih.gov |
| Role of trefoil factor family proteins in beta cell function. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,678,509 | January 20, 2023 | November 30, 2026 | KU, HSUN TERESA | reporter.nih.gov |
| Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia | NIH | National Cancer Institute | 2021 to 2024 | $1,669,514 | April 1, 2020 | March 31, 2025 | WANG, LILI | reporter.nih.gov |
| The function and underlying mechanism of TET1 in myelodysplastic syndromes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,663,013 | March 10, 2020 | December 31, 2023 | CHEN, JIANJUN | reporter.nih.gov |
| A Multimedia Self-Management Intervention to Prepare Family Caregivers and Patients for Lung Cancer Surgery | NIH | National Cancer Institute | 2021 to 2022 | $1,642,908 | September 18, 2018 | August 31, 2024 | SUN, VIRGINIA CHIH-YI | reporter.nih.gov |
| Okazaki fragment maturation: mutagenesis and cell survival | NIH | National Cancer Institute | 2023 to 2025 | $1,616,011 | April 1, 2023 | March 31, 2028 | SHEN, BINGHUI | reporter.nih.gov |
| Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,582,376 | September 1, 2023 | August 31, 2028 | BADIE, BEHNAM | reporter.nih.gov |
| Development of Microbial-Based Therapies to Suppress Macropinocytosis in Kras-Driven Cancers | NIH | National Cancer Institute | 2022 to 2025 | $1,582,219 | July 1, 2022 | June 30, 2027 | MANUEL, EDWIN | reporter.nih.gov |
| Fatty acids and their receptors-mediated tumor metastasis and progression | NIH | National Cancer Institute | 2021 to 2024 | $1,574,167 | February 14, 2020 | January 31, 2026 | YU, HUA E | reporter.nih.gov |
| Bile acids and metabolic surgery | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,568,160 | September 14, 2020 | May 31, 2026 | HUANG, WENDONG | reporter.nih.gov |
| Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,562,097 | August 1, 2020 | April 30, 2027 | WILLIAMS, TERENCE MARQUES | reporter.nih.gov |
| Early Life Exposure to Endocrine Disrupting Chemicals: Epigenomic and Transcriptomic Networks and RAGE in Liver Disease | NIH | National Institute of Environmental Health Sciences | 2024 to 2025 | $1,535,323 | April 17, 2024 | March 31, 2027 | TREVINO, LINDSEY STARR | reporter.nih.gov |
| Cancer Genetics Professional Education in a Global Community of Practice | NIH | National Cancer Institute | 2021 to 2025 | $1,525,426 | September 19, 2013 | August 31, 2028 | BLAZER, KATHLEEN R. | reporter.nih.gov |
| Targeting the Microenvironment/Oncogene Cooperation to treat poor prognosis T-ALL | NIH | National Cancer Institute | 2023 to 2025 | $1,520,378 | March 9, 2023 | February 29, 2028 | CARLESSO, NADIA | reporter.nih.gov |
| Transforming growth factor beta1, microRNAs, lncRNA and diabetic nephropathy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,517,526 | May 1, 2009 | June 30, 2025 | NATARAJAN, RAMA | reporter.nih.gov |
| Exosomal Biomarkers for the Noninvasive Detection of Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,510,680 | August 20, 2019 | July 31, 2025 | GOEL, AJAY | reporter.nih.gov |
| Long non-coding RNA-mediated chromatin remodeling in angiogenesis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,498,278 | July 1, 2019 | June 30, 2024 | CHEN, ZHEN BOUMAN | reporter.nih.gov |
| An integrated toolkit combining computational systems biology techniques with molecular dynamics simulations to delineate functionality of GPCRs | NIH | National Library of Medicine | 2022 to 2025 | $1,496,000 | July 5, 2022 | March 31, 2027 | VAIDEHI, NAGARAJAN | reporter.nih.gov |
| Yes 2 Success | NIH | National Cancer Institute | 2021 to 2023 | $1,457,997 | September 19, 2018 | February 28, 2025 | SISTRUNK, CHRISTOPHER M. | reporter.nih.gov |
| Mammary Adipocyte Remodeling in Health and Disease | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $1,446,245 | April 14, 2020 | February 28, 2026 | WANG, QIONG ANNABEL | reporter.nih.gov |
| Defining the Role of Adipogenesis in Age-Associated Adiposity | NIH | National Institute on Aging | 2021 to 2024 | $1,443,200 | May 15, 2020 | April 30, 2026 | WANG, QIONG ANNABEL | reporter.nih.gov |
| Targeting Protein Arginine Methyltransferases to Eradicate Acute Myeloid Leukemia | NIH | National Cancer Institute | 2024 to 2025 | $1,435,114 | December 8, 2023 | November 30, 2028 | LI, LING | reporter.nih.gov |
| Structural dynamics underlying GPCR-G protein selectivity | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,400,400 | May 17, 2017 | January 31, 2026 | VAIDEHI, NAGARAJAN | reporter.nih.gov |
| The role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AML | NIH | National Cancer Institute | 2021 to 2023 | $1,361,506 | February 1, 2019 | January 31, 2024 | CHEN, JIANJUN | reporter.nih.gov |
| RNA-mediated endotheliopathy in diabetic vasculopathy | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,357,054 | July 1, 2024 | June 30, 2031 | CHEN, ZHEN BOUMAN | reporter.nih.gov |
| Quantitative MRI to automatically delineate intraprostatic tumor for radiation therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,353,393 | July 1, 2024 | June 30, 2029 | QING, KUN | reporter.nih.gov |
| Circadian clock and temporal control in nutrient metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,343,295 | September 1, 2023 | June 30, 2027 | MA, KE | reporter.nih.gov |
| Regulation of N6-methyladenosine (m6A) deposition by arginine methylation | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,318,800 | August 1, 2019 | April 30, 2025 | YANG, YANZHONG | reporter.nih.gov |
| Role of BAZ2A in MLL-r leukemia and therapeutic response | NIH | National Cancer Institute | 2021 to 2023 | $1,311,299 | April 1, 2019 | March 31, 2024 | CHEN, CHUN-WEI DAVID | reporter.nih.gov |
| Define the oncogenic role of METTL3 in the pathogenesis of chronic lymphocytic leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,310,217 | July 1, 2023 | October 30, 2025 | WANG, LILI | reporter.nih.gov |
| Regulation of beta-cell homeostasis by DNA methylation and hydroxymethylation. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,297,500 | April 1, 2019 | January 31, 2025 | DHAWAN, SANGEETA | reporter.nih.gov |
| Regulating SNARE mechanisms to remediate glucose homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,297,500 | September 11, 2019 | July 31, 2025 | THURMOND, DEBBIE C | reporter.nih.gov |
| Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,292,812 | July 15, 2023 | June 30, 2028 | SWAMINATHAN, SRIVIDYA | reporter.nih.gov |
| FEN1-mediated Okazaki fragment maturation and its deficiency in cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,259,788 | May 1, 1997 | April 30, 2029 | SHEN, BINGHUI | reporter.nih.gov |
| Targeting bile acid composition to treat metabolic diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,250,747 | January 19, 2024 | December 31, 2027 | HUANG, WENDONG | reporter.nih.gov |
| Ionizing Radiation-Induced DNA damage repair | NIH | National Cancer Institute | 2021 to 2023 | $1,245,640 | May 1, 2009 | August 31, 2025 | LIU, YILUN | reporter.nih.gov |
| Dynamic functions of DNA2 counteract DNA replication stresses and tumorigenesis | NIH | National Cancer Institute | 2021 to 2024 | $1,225,676 | July 1, 1999 | April 30, 2026 | SHEN, BINGHUI | reporter.nih.gov |
| A Prospective Cohort Study of Patients with Non-Small Cell Lung Cancer and Multiple Myeloma to Assess the Benefits and Harms Related to Cannabis Use During Treatment | NIH | National Cancer Institute | 2023 to 2024 | $1,194,966 | September 20, 2023 | August 31, 2028 | LEE, RICHARD T | reporter.nih.gov |
| Biological function and regulation of PRMT9 in synapse development | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,191,957 | February 5, 2024 | January 31, 2029 | YANG, YANZHONG | reporter.nih.gov |
| Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma | NIH | National Cancer Institute | 2021 to 2023 | $1,191,696 | August 1, 2019 | July 31, 2025 | PICHIORRI, FLAVIA | reporter.nih.gov |
| State-transition and leukemia potential dynamics to inform disease evolution and adaptive therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,181,920 | September 19, 2024 | August 31, 2029 | ROCKNE, RUSSELL CHRISTIAN | reporter.nih.gov |
| RECQ5-dependent SUMO2 conjugation of PCNA in the resolution of transcription-replication conflicts | NIH | National Cancer Institute | 2021 to 2023 | $1,171,384 | February 1, 2019 | January 31, 2026 | LIU, YILUN | reporter.nih.gov |
| The role of O-GlcNAcylation in DNA damage repair and cancer therapy | NIH | National Cancer Institute | 2021 to 2023 | $1,171,384 | June 1, 2019 | May 31, 2025 | STARK, JEREMY MICHAEL | reporter.nih.gov |
| Interdisciplinary Communication Training in Oncology | NIH | National Cancer Institute | 2021 to 2024 | $1,168,671 | March 6, 2020 | February 28, 2025 | FERRELL, BETTY R | reporter.nih.gov |
| BMT CTN Core - City of Hope National Medical Center | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,150,800 | September 30, 2001 | June 30, 2031 | NAKAMURA, RYOTARO | reporter.nih.gov |
| Targeting Immune Escape in CML/MPN Transformation | NIH | National Cancer Institute | 2024 to 2025 | $1,143,230 | December 8, 2023 | November 30, 2028 | ZHANG, BIN | reporter.nih.gov |
| The role of bile acid metabolomics in graft-versus-host disease | NIH | National Cancer Institute | 2024 to 2025 | $1,141,462 | March 15, 2024 | March 31, 2028 | VAN DEN BRINK, MARCEL R M | reporter.nih.gov |
| Preparing Oncology Advanced Practice Nurses as Generalists in Palliative Care | NIH | National Cancer Institute | 2021 to 2025 | $1,135,711 | August 16, 2017 | February 29, 2028 | FERRELL, BETTY R | reporter.nih.gov |
| Mechanism and therapeutic opportunities of targeting the Tudor domain | NIH | National Cancer Institute | 2023 to 2025 | $1,132,200 | December 1, 2022 | February 16, 2025 | CHEN, CHUN-WEI DAVID | reporter.nih.gov |
| Limited Competition for the Continuation of the Intestinal Stem Cell Consortium Coordinating Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,106,182 | September 30, 2009 | August 31, 2025 | NILAND, JOYCE CAROL | reporter.nih.gov |
| A Novel Bone Marrow Transplantation Approach for Sickle Cell Disease Using Targeted Marrow Irradiation | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,049,350 | July 1, 2023 | June 30, 2027 | HUI, SUSANTA K | reporter.nih.gov |
| Cancer Metabolism Training Program | NIH | National Cancer Institute | 2021 to 2025 | $981,774 | September 1, 2018 | May 31, 2029 | ANN, DAVID K. | reporter.nih.gov |
| DNA Damage Response and Oncogenic Signaling | NIH | National Cancer Institute | 2022 to 2025 | $958,151 | July 14, 2016 | February 28, 2027 | STARK, JEREMY MICHAEL | reporter.nih.gov |
| Impact of the Therapeutic Alliance on Reduction of Disparities in Latino End-of-Life Cancer Care | NIH | National Cancer Institute | 2021 to 2024 | $951,463 | May 1, 2020 | April 30, 2025 | TERGAS, ANA ISABEL | reporter.nih.gov |
| Mechanism and therapeutic implication of RNA-modification-mediated codon-biased translation in acute myeloid leukemia | NIH | National Cancer Institute | 2025 | $941,798 | August 6, 2025 | July 31, 2030 | CHEN, JIANJUN | reporter.nih.gov |
| Cell-Selective CpG-STAT3 Inhibitors for Radioimmunotherapy of Malignant Glioma | NIH | National Cancer Institute | 2021 to 2022 | $907,797 | September 1, 2018 | August 31, 2024 | KORTYLEWSKI, MARCIN | reporter.nih.gov |
| The role, mechanism, and therapeutic potential of METTL1 in acute myeloid leukemia | NIH | National Cancer Institute | 2024 to 2025 | $877,852 | June 14, 2024 | May 31, 2029 | SU, RUI | reporter.nih.gov |
| Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors | NIH | National Cancer Institute | 2022 to 2023 | $874,303 | August 9, 2022 | July 5, 2024 | VILLALONA, MIGUEL A | reporter.nih.gov |
| Targeting protein acetylation as a therapeutic approach for MDS | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $865,000 | March 3, 2018 | February 29, 2024 | LI, LING | reporter.nih.gov |
| The role of hyaluron in beige adipogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $849,788 | September 5, 2025 | June 30, 2030 | WANG, QIONG ANNABEL | reporter.nih.gov |
| Role of UPR transducer Xbp1 in Pancreatic Beta Cell Survival and Function under Metabolic Stress | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $847,746 | September 1, 2025 | August 31, 2030 | DENG, YINGFENG | reporter.nih.gov |
| Elucidating the Cellular Origins of lung adenocarcinoma | NIH | National Cancer Institute | 2023 to 2025 | $841,766 | July 11, 2023 | April 30, 2029 | MARCONETT, CRYSTAL NICOLE | reporter.nih.gov |
| Randomized Trial of Exercise Therapy on Markers of Progression in Localized Prostate Cancer | NIH | National Cancer Institute | 2025 | $839,781 | September 15, 2022 | July 31, 2027 | JONES, LEE W | reporter.nih.gov |
| Mentoring the Next Generation of Geriatric Oncology and Supportive Care Researchers in Patient-Oriented Research to Improve the Care of Older Adults with Cancer | NIH | National Institute on Aging | 2021 to 2025 | $816,905 | December 1, 2017 | May 31, 2028 | DALE, WILLIAM | reporter.nih.gov |
| Microenvironmental cues control pancreas cell fate and beta-cell maturation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $816,416 | September 15, 2018 | July 31, 2024 | SHIH, HUNG-PING | reporter.nih.gov |
| BCL11B activation as an approach for enhancing the efficacy of immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $811,046 | February 11, 2021 | January 31, 2026 | PAREKH, CHINTAN | reporter.nih.gov |
| Discovery and validation of CYP8B1 Inhibitors as probes for targeting Hepatocellular Carcinomas (HCC) | NIH | National Cancer Institute | 2025 | $793,324 | April 15, 2025 | March 31, 2028 | HUANG, WENDONG | reporter.nih.gov |
| PD-L1 interacts with CD80 and PD-1 to regulate GVHD and GVL activity | NIH | National Cancer Institute | 2021 to 2022 | $783,945 | March 1, 2018 | February 28, 2023 | ZENG, DEFU | reporter.nih.gov |
| Androgen Signaling in Prostatic Sonic Hedgehog Responsive Cells | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $774,400 | September 1, 2015 | May 31, 2025 | SUN, ZIJIE | reporter.nih.gov |
| Overcoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-Cadherin | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $749,824 | February 1, 2018 | April 24, 2024 | YU, JIANHUA | reporter.nih.gov |
| Investigating the Role of Radiation-induced Cell Death in Innate Lymphoid Cell Activation within Unique Tumor Microenvironments | NIH | National Cancer Institute | 2022 to 2024 | $747,000 | December 1, 2021 | March 31, 2026 | MCGEE, HEATHER MICHELLE | reporter.nih.gov |
| CMV-specific CD19 CAR T cells amplified in vivo using CMV Triplex vaccine for B-NHL | NIH | National Cancer Institute | 2025 | $738,698 | December 1, 2024 | November 30, 2029 | WANG, XIULI | reporter.nih.gov |
| Anti-CD38 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Myelogenous Leukemia | NIH | National Cancer Institute | 2025 | $738,698 | March 7, 2025 | February 28, 2030 | WONG, JEFFREY Y | reporter.nih.gov |
| High Fidelity Genome Editing for the Correction of MECP2 Mutations and Physiologic Regulation of Expression in Rett Syndrome | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $738,182 | April 15, 2025 | February 28, 2030 | CHATTERJEE, SASWATI | reporter.nih.gov |
| Targeting AMP Synthesis to Overcome Resistance to BH3 Mimetics in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2025 | $734,435 | March 10, 2025 | February 28, 2030 | LI, LING | reporter.nih.gov |
| Chromatin remodeling factors and mechanisms in diabetic microvascular complications | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $726,922 | August 20, 2025 | June 30, 2030 | NATARAJAN, RAMA | reporter.nih.gov |
| Attacking the Tumor Cell-Immune Milieu Interface to Overcome Richter's Transformation | NIH | National Cancer Institute | 2025 | $721,723 | December 16, 2024 | November 30, 2029 | WANG, LILI | reporter.nih.gov |
| Targeting Tumor-Associated Macrophages to Treat Lymphoma | NIH | National Cancer Institute | 2025 | $702,495 | August 1, 2025 | July 31, 2030 | HUANG, WENDONG | reporter.nih.gov |
| Epigenetic damage in women living in LA food-desert zip codes | NIH | National Cancer Institute | 2021 | $700,381 | August 1, 2017 | July 31, 2022 | SEEWALDT, VICTORIA L. | reporter.nih.gov |
| Novel mechanisms and therapeutics for Tyrosine Kinase Inhibitor-induced Cardiotoxicity | NIH | National Heart, Lung, and Blood Institute | 2025 | $697,952 | May 15, 2025 | February 28, 2030 | RHEE, JUNE-WHA | reporter.nih.gov |
| Exercise as Interception Therapy in Primary High Risk Cancer | NIH | National Cancer Institute | 2025 | $693,662 | September 3, 2020 | June 30, 2027 | JONES, LEE W | reporter.nih.gov |
| 5mC and 5hmC DNA alterations as sensitive and specific biomarkers for the non-invasive early detection of pancreatic ductal adenocarcinoma | NIH | National Cancer Institute | 2025 | $690,637 | September 1, 2025 | August 31, 2030 | GOEL, AJAY | reporter.nih.gov |
| Use of a non-human primate model to define the role of T cell immune responses in persistent Kaposi sarcoma-associated herpesvirus infection and Kaposi sarcoma pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $672,032 | February 1, 2023 | June 30, 2024 | MUTSVUNGUMA, LORRAINE ZVICHAPERA | reporter.nih.gov |
| Tumor-Selective Radiosensitization by Targeting Hypoxia in Rectal Cancer | NIH | National Cancer Institute | 2025 | $662,096 | February 1, 2025 | January 31, 2030 | WILLIAMS, TERENCE MARQUES | reporter.nih.gov |
| Role of RNA modification in innate immune cell development and function | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $659,663 | August 1, 2025 | July 31, 2030 | MA, SHOUBAO | reporter.nih.gov |
| Epigenetic regulation of genomic stability in beta-cell homeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $641,794 | July 21, 2025 | April 30, 2030 | DHAWAN, SANGEETA | reporter.nih.gov |
| Define the effect of CLU SNP on the risk to Alzheimer's disease | NIH | National Institute on Aging | 2025 | $634,699 | August 1, 2022 | July 31, 2027 | SHI, YANHONG | reporter.nih.gov |
| Transcriptional control, targeted modification, and excision of HIV in the brain | NIH | National Institute of Mental Health | 2021 | $605,271 | April 14, 2017 | January 6, 2023 | BURNETT, JOHN CORY | reporter.nih.gov |
| Patient-specific modeling of metabolic dysfunction in statin-induced myopathy using iPSC-derived myocytes | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $593,872 | August 15, 2020 | October 31, 2025 | RHEE, JUNE-WHA | reporter.nih.gov |
| The role of IL-6/STAT3 signaling in CIC-DUX4 fusion sarcoma metastasis and immunosuppression | NIH | National Cancer Institute | 2025 | $593,028 | April 3, 2025 | March 31, 2030 | YU, HUA E | reporter.nih.gov |
| Identification of metabolic adducts associated with prostate cancer progression in African American men Supplement | NIH | National Cancer Institute | 2023 to 2024 | $578,552 | March 1, 2024 | August 31, 2025 | SHUCK, SARAH C. | reporter.nih.gov |
| Improving Outcomes for Multiple Myeloma Patients through Novel Therapeutic Interventions | NIH | National Cancer Institute | 2021 to 2025 | $564,465 | September 21, 2021 | August 31, 2026 | CASERTA, ENRICO | reporter.nih.gov |
| Reolysin-based combination therapy in relapsed multiple myeloma | NIH | National Cancer Institute | 2021 | $532,313 | September 1, 2016 | August 31, 2023 | PICHIORRI, FLAVIA | reporter.nih.gov |
| Scalable Bayesian Network analysis of multimodal FACS and SUMOylation data, with generalization to other big mixed biological datasets | NIH | National Library of Medicine | 2021 to 2022 | $523,600 | July 1, 2020 | January 31, 2024 | RODIN, ANDREI | reporter.nih.gov |
| Inflammation as determinant of clonal selection in MPN progression | NIH | National Heart, Lung, and Blood Institute | 2021 | $522,957 | September 15, 2018 | June 30, 2023 | CARLESSO, NADIA | reporter.nih.gov |
| The Role and Function of a Novel Signature Gene in BCR::ABL1 (Ph) B-cell Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2025 | $517,090 | August 18, 2025 | July 31, 2030 | GU, ZHAOHUI | reporter.nih.gov |
| Characterization of novel subtypes in B progenitor acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2022 | $498,000 | July 13, 2020 | June 30, 2023 | GU, ZHAOHUI | reporter.nih.gov |
| A Blended e-Health Intervention for Fear of Progression in Advanced GYN Cancer | NIH | National Cancer Institute | 2024 | $489,500 | September 1, 2024 | August 31, 2026 | REB, ANNE | reporter.nih.gov |
| Targeting mitochondrial RNA methylation in high-risk acute myeloid leukemia | NIH | National Cancer Institute | 2025 | $487,542 | December 10, 2024 | November 30, 2029 | SU, RUI | reporter.nih.gov |
| Function of TCF-1 in antagonizing malignancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $484,000 | August 1, 2021 | July 31, 2023 | SUN, ZUOMING | reporter.nih.gov |
| Dissecting the Functional Role of PAX5 Mutations in B-cell Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2025 | $483,110 | September 1, 2025 | August 31, 2030 | GU, ZHAOHUI | reporter.nih.gov |
| Genomic Analysis of Cutaneous CD30+ Lymphoproliferative Disorders | NIH | National Cancer Institute | 2022 to 2023 | $482,803 | February 1, 2022 | January 31, 2025 | SONG, JOO | reporter.nih.gov |
| Cancer Aging and Metabolism research experience Program (CAMP) | NIH | National Cancer Institute | 2024 to 2025 | $479,848 | June 21, 2024 | May 31, 2029 | ANN, DAVID K. | reporter.nih.gov |
| Development of Family1st-An interactive web-based tool with evidence-based approaches to communicate hereditary cancer risk to at risk relatives and promote cascade testing. | NIH | National Cancer Institute | 2022 | $476,880 | September 19, 2022 | August 31, 2025 | GRAY, STACY W. | reporter.nih.gov |
| PITT-CAL ETCTN PK Resource Laboratory | NIH | National Cancer Institute | 2025 | $472,785 | January 1, 2025 | February 28, 2027 | SYNOLD, TIMOTHY W | reporter.nih.gov |
| Modeling and Targeting B/Myeloid Mixed Phenotype Acute Leukemia | NIH | National Cancer Institute | 2022 to 2023 | $462,952 | March 3, 2022 | February 29, 2024 | CHEN, WENYONG | reporter.nih.gov |
| Non-receptor protein tyrosine phosphatases in macrophage-mediated cancer cell phagocytosis. | NIH | National Cancer Institute | 2024 to 2025 | $457,683 | March 1, 2024 | August 31, 2026 | FENG, MINGYE | reporter.nih.gov |
| Developing a novel therapeutic strategy for overcoming resistance to PD-1 blockade in Triple-negative breast cancer | NIH | National Cancer Institute | 2024 to 2025 | $457,683 | February 1, 2024 | January 31, 2027 | ZHANG, CHUNYAN | reporter.nih.gov |
| Modulating Intratumoral Immune Composition to Enhance Immunotherapy | NIH | National Cancer Institute | 2024 | $457,683 | July 2, 2024 | June 30, 2026 | MANUEL, EDWIN | reporter.nih.gov |
| Targeting TET1 signaling to treat acute myeloid leukemia | NIH | National Cancer Institute | 2021 | $457,310 | January 1, 2017 | December 31, 2021 | CHEN, JIANJUN | reporter.nih.gov |
| 1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership | NIH | National Cancer Institute | 2021 to 2022 | $453,512 | September 2, 2019 | August 31, 2024 | SEEWALDT, VICTORIA L. | reporter.nih.gov |
| A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy | NIH | National Cancer Institute | 2022 | $452,540 | September 23, 2022 | August 31, 2025 | LEE, RICHARD T | reporter.nih.gov |
| Inflammatory Gene Regulation in Diabetic Conditions | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $450,821 | July 1, 2003 | June 30, 2023 | NATARAJAN, RAMA | reporter.nih.gov |
| The role of ALKBH5-mediated RNA demethylation in the maintenance of genomic stability in HSPCs | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $450,479 | January 13, 2026 | May 31, 2027 | QIAN, ZHIJIAN | reporter.nih.gov |
| Effects of tumor-microbial interactions on EGFR-targeted therapy resistance in lung cancer | NIH | National Cancer Institute | 2021 to 2022 | $448,427 | July 9, 2021 | June 30, 2023 | RAZ, DAN J | reporter.nih.gov |
| Utilizing Hybrid Antigen-Presenting Neutrophils to Prime WT1-Specific Immune Responses as Therapy for Acute Leukemia | NIH | National Cancer Institute | 2022 to 2023 | $448,427 | December 1, 2021 | November 30, 2024 | MANUEL, EDWIN | reporter.nih.gov |
| Integrated Genotypic, Phenotypic and Immunologic Analysis of Ethnically Diverse Prostate Cancers | NIH | National Cancer Institute | 2022 to 2023 | $448,427 | March 10, 2022 | February 28, 2025 | DORFF, TANYA | reporter.nih.gov |
| Targeting MUC16 transactivation for ovarian cancer treatment | NIH | National Cancer Institute | 2022 to 2023 | $447,603 | January 1, 2022 | December 31, 2025 | WANG, EDWARD WENGE | reporter.nih.gov |
| Modeling Alzheimer’s disease using directly reprogrammed isogenic neural cells | NIH | National Institute on Aging | 2021 | $445,140 | August 1, 2017 | April 30, 2023 | SHI, YANHONG | reporter.nih.gov |
| Protein arginine methylation in transcription and RNA metabolism | NIH | National Institute of General Medical Sciences | 2025 | $445,000 | January 23, 2025 | December 31, 2029 | YANG, YANZHONG | reporter.nih.gov |
| Emergent role of allostery on function of GPCRs and Trimeric G proteins | NIH | National Institute of General Medical Sciences | 2025 | $445,000 | February 1, 2025 | January 31, 2030 | VAIDEHI, NAGARAJAN | reporter.nih.gov |
| Role of UPR transducer Xbp1 in Pancreatic Beta Cell Survival and Function under Metabolic Stress | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 | $444,867 | September 1, 2024 | August 31, 2025 | DENG, YINGFENG | reporter.nih.gov |
| Bone Marrow Niche dysfunction in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 | $443,011 | February 4, 2021 | April 30, 2022 | CARLESSO, NADIA | reporter.nih.gov |
| Perioperative Telemonitoring to Optimize Cancer Care and Outcomes | NIH | National Institute of Nursing Research | 2021 to 2022 | $440,000 | April 14, 2021 | November 30, 2023 | MELSTROM, LALEH | reporter.nih.gov |
| Epigenetic changes and methylglyoxal adducts induced by metabolic regulation in patients with type 1 diabetes that develop complications | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $440,000 | September 15, 2020 | July 31, 2023 | SHUCK, SARAH C. | reporter.nih.gov |
| Intestinal Regulation of Gut Microbiota and Metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $440,000 | July 1, 2021 | June 30, 2023 | HUANG, WENDONG | reporter.nih.gov |
| Circadian clock regulation of metabolic pathways in aging | NIH | National Institute on Aging | 2023 | $440,000 | September 15, 2023 | August 31, 2025 | MA, KE | reporter.nih.gov |
| Novel Neurosurgical Device for Evacuation of Intracerebral Hematoma | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $439,239 | July 1, 2025 | June 30, 2030 | BADIE, BEHNAM | reporter.nih.gov |
| New Insight of Androgen Signaling in Prostate Cancer Initiation and Progression | NIH | National Cancer Institute | 2022 to 2023 | $437,000 | July 23, 1997 | March 31, 2024 | SUN, ZIJIE | reporter.nih.gov |
| Circadian Clock Control of Adipose Depot Development and Function | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $432,500 | December 1, 2017 | November 30, 2022 | MA, KE | reporter.nih.gov |
| DOC2B-based therapeutics for prevention/remediation of type 2 diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $432,500 | June 1, 2018 | May 31, 2023 | THURMOND, DEBBIE C | reporter.nih.gov |
| Epigenetic dysregulation of transposons in obesity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $432,500 | September 1, 2017 | June 30, 2023 | SCHONES, DUSTIN EDWARD | reporter.nih.gov |
| Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 | $430,377 | February 16, 2017 | December 31, 2022 | KORTYLEWSKI, MARCIN | reporter.nih.gov |
| The role and mechanism of FTO in leukemogenesis and drug response | NIH | National Cancer Institute | 2021 | $426,319 | April 1, 2017 | March 31, 2022 | CHEN, JIANJUN | reporter.nih.gov |
| Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia | NIH | National Cancer Institute | 2022 to 2023 | $425,203 | March 1, 2022 | February 28, 2025 | WONG, JEFFREY Y | reporter.nih.gov |
| Elucidate and Modulate Cell Signaling in NK Cells for Glioma Treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $420,175 | July 18, 2017 | June 30, 2023 | YU, JIANHUA | reporter.nih.gov |
| Leading NCI Clinical Trials Network research nationally and at the City of Hope Comprehensive Cancer Center | NIH | National Cancer Institute | 2024 to 2025 | $416,206 | September 1, 2024 | August 31, 2029 | HERRERA, ALEX F. | reporter.nih.gov |
| Concurrent eradication of pathogenic plasma cells and their precursors in systemic lupus erythematosus | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 | $415,414 | September 18, 2024 | August 31, 2026 | SWAMINATHAN, SRIVIDYA | reporter.nih.gov |
| Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumors | NIH | National Cancer Institute | 2021 | $410,877 | September 7, 2011 | March 31, 2022 | BADIE, BEHNAM | reporter.nih.gov |
| MiRNAs in hepatocellular carcinoma development and treatment | NIH | National Cancer Institute | 2021 | $410,875 | January 25, 2011 | May 31, 2023 | HUANG, WENDONG | reporter.nih.gov |
| Remote monitoring of cardiac function in childhood cancer survivors | NIH | National Cancer Institute | 2021 to 2022 | $396,713 | July 1, 2021 | June 30, 2024 | ARMENIAN, SARO | reporter.nih.gov |
| Develop novel inhaled neutralizing RNA therapeutics against COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $396,000 | July 6, 2021 | June 30, 2024 | ROSSI, JOHN JOSEPH | reporter.nih.gov |
| DIABETES PREVENTION / RISK / OMICS / METABOLISM / THERAPY (PROMT) INTERDISCIPLINARY TRAINING | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $386,591 | April 1, 2023 | March 31, 2028 | THURMOND, DEBBIE C | reporter.nih.gov |
| The role of YTHDC1 in normal and malignant hematopoiesis | NIH | National Cancer Institute | 2025 | $386,344 | May 10, 2022 | November 30, 2027 | QIAN, ZHIJIAN | reporter.nih.gov |
| Role of the TET1 short isoform in MDS development and maintenance | NIH | National Heart, Lung, and Blood Institute | 2025 | $371,790 | January 20, 2022 | December 31, 2026 | QIAN, ZHIJIAN | reporter.nih.gov |
| Vascular network-mimetic oxygen-transporting mesh for islet graft | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $352,978 | August 4, 2021 | April 30, 2023 | KOMATSU, HIROTAKE | reporter.nih.gov |
| The function of Topoisomerase I SUMOylation in transcription and chemoresistance | NIH | National Institute of General Medical Sciences | 2021 | $346,000 | May 1, 2018 | March 31, 2023 | LIU, YILUN | reporter.nih.gov |
| Role of Autoreactivity in pathogenesis of chronic graft versus host disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $342,596 | July 1, 2005 | May 31, 2022 | ZENG, DEFU | reporter.nih.gov |
| Multi-antigen-specific CAR T cells to treat acute myeloid leukemia | NIH | National Cancer Institute | 2024 | $263,034 | September 1, 2024 | August 31, 2025 | JAMES, SCOTT E | reporter.nih.gov |
| PRODUCTION ASSISTANCE FOR CELLULAR THERAPIES (PACT)- CELL PROCESSING FACILITIES CELL-TASK AREA 2, PCT0050-01: HESC-DERIVED CARDIOMYOCYTE PROGENITOR CE | NIH | National Heart, Lung, and Blood Institute | 2021 | $251,745 | October 20, 2020 | July 20, 2021 | GOLD, JOSEPH | reporter.nih.gov |
| Targeting Senescence to Improve Frailty in Older Cancer Survivors | NIH | National Institute on Aging | 2022 | $243,000 | August 1, 2022 | May 31, 2023 | SEDRAK, MINA S | reporter.nih.gov |
| Conjugated bile acids as metabolic mediators between gut and fat tissues | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 | $222,500 | September 1, 2024 | August 31, 2025 | HUANG, WENDONG | reporter.nih.gov |
| Regulating SNARE mechanisms to remediate glucose dyshomeostasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $222,500 | July 1, 2004 | August 31, 2026 | THURMOND, DEBBIE C | reporter.nih.gov |
| Immune Evasion Mechanisms of KSHV Complement and Fc-Receptor Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $219,720 | September 12, 2022 | September 11, 2024 | MUNIRAJU, MURALI BAGALUR | reporter.nih.gov |
| Stearoyl-CoA Desaturase in Alcohol-Promoted Liver Tumorigenesis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $195,588 | May 1, 2017 | April 30, 2023 | LAI, KEANE | reporter.nih.gov |
| Determinants of Resistance to Engineered T-cell Therapies Targeting CD19 in Lymphoma | NIH | National Cancer Institute | 2025 | $188,301 | September 1, 2023 | June 30, 2028 | SWORDER, BRIAN | reporter.nih.gov |
| Determinants of Repeat Colorectal Cancer Screening in a Safety-Net System | NIH | National Cancer Institute | 2022 to 2023 | $180,582 | July 1, 2022 | June 30, 2025 | NONZEE, NARISSA JENNIFER | reporter.nih.gov |
| Protein Phosphoribosylation: Characterization of a novel protein modification | NIH | National Institute of Dental & Craniofacial Research | 2025 | $178,000 | April 1, 2025 | March 31, 2027 | FENG, SHU | reporter.nih.gov |
| Evaluating the ELF5 Clock as a Biomarker in Breast Cancer Prevention Trials | NIH | National Cancer Institute | 2025 | $178,000 | June 23, 2025 | May 31, 2027 | MIYANO, MASARU | reporter.nih.gov |
| Targeting the ARHGAP25 pathway in acute myelogenous leukemia stem cells | NIH | National Cancer Institute | 2021 | $169,560 | July 1, 2017 | June 30, 2022 | WANG, LEO D. | reporter.nih.gov |
| Alpha Cell Heterogeneity: Unveiling Novel Targets for T1D therapy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $153,554 | September 15, 2025 | July 31, 2030 | PANZER, JULIA KATHARINA | reporter.nih.gov |
| The role of Nrf2 in beta cell expansion during pregnancy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $153,554 | February 1, 2022 | November 30, 2025 | ALTERZON, SHARON | reporter.nih.gov |
| The gut-fat crosstalk in metabolic regulation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $140,116 | September 15, 2025 | July 31, 2028 | ZHANG, ERYUN | reporter.nih.gov |
| Using Cultured Human Mammary Epithelial Cells to Explore the Role of the Yap Oncogene in Early Breast Cancer Progression | NIH | National Cancer Institute | 2021 to 2022 | $130,972 | September 29, 2020 | August 11, 2023 | FRESQUES, TARA MICOLE | reporter.nih.gov |
| Impact of RNA splicing factor mutations on circular RNA biogenesis in leukemia | NIH | National Cancer Institute | 2021 to 2024 | $125,536 | September 1, 2021 | August 31, 2025 | FERNANDEZ, MIKE | reporter.nih.gov |
| Mitigation of lymphatic injury by retinoic acid therapyin a large animal model | NIH | National Heart, Lung, and Blood Institute | 2021 | $88,000 | July 1, 2021 | June 30, 2023 | WONG, ALEX K. | reporter.nih.gov |
| Fcγ Receptor-Mediated Pharmacogenomics of Antibody Therapies in Type 1 Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $87,573 | December 1, 2025 | August 31, 2026 | SHAPIRO, MELANIE R | reporter.nih.gov |
| Characterization of CEACAM1 as a novel therapeutic in mantle cell lymphoma | NIH | National Cancer Institute | 2021 | $82,280 | December 1, 2019 | November 30, 2021 | NGO, VU NGUYEN | reporter.nih.gov |
| Cytomegalovirus-specific Immune Reconstitution after Hematopoietic Cell Transplantation in the Era of Modern Antiviral Prophylaxis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $79,530 | February 7, 2022 | January 31, 2027 | ZAMORA, DANNIEL | reporter.nih.gov |
| Exploiting Caveolae-Dependent Albumin Endocytosis to optimize Therapy in Pancreatic Cancer | NIH | National Cancer Institute | 2021 | $77,289 | April 1, 2016 | March 31, 2023 | WILLIAMS, TERENCE MARQUES | reporter.nih.gov |
| Development of novel CYP8B1 inhibitors | NIH | National Cancer Institute | 2024 | $74,284 | May 1, 2024 | April 30, 2025 | AGUA, ALON ROY LLAGAS | reporter.nih.gov |
| Defining synthetic lethal relationships with loss of the homologous recombination factor Rad52 | NIH | National Cancer Institute | 2023 | $69,500 | April 1, 2023 | March 31, 2024 | OSIA, BETH ANNE | reporter.nih.gov |
| Using Senolytics to Improve Physical Function in Older Breast Cancer Survivors | NIH | National Cancer Institute | 2023 | $66,006 | December 22, 2022 | June 30, 2023 | SEDRAK, MINA S | reporter.nih.gov |
| SCH: Collaborative Research: Comprehensive Tissue Disease Diagnosis Using a Multimodal Robotic System | NSF | Civil, Mechanical, & Manufacturing Innovation | 2024 | $50,000 | October 1, 2024 | September 30, 2028 | Mustafa Raoof | nsf.gov |
| Targeting a Novel Pocket on ITGAV | NIH | National Cancer Institute | 2022 to 2023 | $39,141 | August 3, 2022 | September 22, 2023 | MATTSON, NICOLE | reporter.nih.gov |
| Defining the role of chromosomal break end synapsis factors for DNA repair | NIH | National Cancer Institute | 2023 | $33,194 | September 1, 2023 | August 31, 2024 | CISNEROS, METZTLI | reporter.nih.gov |
| Designing Rational Combinations to Improve CAR T Cell Therapy for Prostate Cancer | NIH | National Cancer Institute | 2023 | $31,694 | January 1, 2024 | December 31, 2024 | YOUNG, CARI ALYSIA | reporter.nih.gov |
| 2025 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $20,000 | November 1, 2025 | October 31, 2026 | KANDEEL, FOUAD R | reporter.nih.gov |
| 21st International Conference of the Society for Integrative Oncology | NIH | National Cancer Institute | 2024 | $10,000 | August 1, 2024 | July 31, 2025 | LEE, RICHARD T | reporter.nih.gov |
| Division of Chemical Toxicology Symposia at the 270th National ACS meeting | NIH | National Institute of Environmental Health Sciences | 2025 | $10,000 | August 12, 2025 | July 31, 2026 | SHUCK, SARAH C. | reporter.nih.gov |
| Division of Chemical Toxicology Symposia at the 268th National ACS meeting | NIH | National Institute of Environmental Health Sciences | 2024 | $6,000 | July 1, 2024 | June 30, 2025 | SHUCK, SARAH C. | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 131 | $82,740,323 | 0 | $0 |
| 2024 | 132 | $77,830,261 | 1 | $50,000 |
| 2023 | 145 | $86,289,168 | 0 | $0 |
| 2022 | 132 | $74,268,893 | 0 | $0 |
| 2021 | 130 | $74,784,970 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Topics of its NIH awards
- Cancer
- Genetics
- Rare Diseases
- Clinical Research
- Hematology
- Biotechnology
- Orphan Drug
- Translational Research
- Prevention
- Immunotherapy
- Pediatric
- Clinical Trials and Supportive Activities
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.